Key Highlights
•
A study of 13.9 million Medicare beneficiaries with type 2 diabetes found that only 4.8% initiated semaglutide or tirzepatide in 2023. Minoritized racial and ethnic groups, dual-enrolled individuals, and those living in socially vulnerable neighborhoods had significantly lower odds of receiving these medications.
Source →
•
Research identifies the protein kinase CK2 as a novel therapeutic target for lupus nephritis, which is a key complication in autoimmune diseases like lupus. A CK2 inhibitor, CX-4945, was shown to reduce kidney damage and neutrophil activity in pre-clinical models, suggesting potential for treating diabetic nephropathy and other neutrophil-driven inflammatory conditions.
Source →
Stay curious. Stay informed —
Science Briefing
